The 3D structure of the folded amyloid beta 42 protein (Wikimedia Commons)
Bristol Myers Squibb has licensed an amyloid-beta antibody programme from BioArctic AB. Under this agreement, Bristol Myers Squibb gains exclusive worldwide rights to develop and commercialize these antibodies, which target neurodegenerative diseases such as Alzheimer's.
The PyroGlutamate-amyloid-beta (PyroGlu-Aβ) programme includes novel antibodies (BAN1503 and BAN2803). These target a truncated, pyroglutamate modified form of amyloid-beta. BAN2803 utilises a technology platform (Brain Transporter technology) that optimises biologic drug delivery past the blood brain barrier. Under the agreement, BioArctic will receive a $100 million, up to $1.25 billion in milestone payments as well as royalties on worldwide product sales.
BrainTransporterTM technology
BioArctic’s BrainTransporter technology is a technology for facilitating the passage of biological drugs as for example antibodies into the brain using the transferrin receptor (TfR). Active transport of biotherapeutics across the blood brain barrier can result in broader brain distribution enabling better efficacy, improved safety profile and dosing convenience. The technology is being applied to several in-house drug projects and could become part of future collaborations with other pharma companies.
Bron: BioArctic: BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program